Analytical Data
-
Gene name
IFNA17
- Application
-
Alternative Names
IFNA17；Interferon alpha-17
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
P01571
-
Expression Region
24-189aa
-
AA Sequence
CDLPQTHSLGNRRALILLAQMGRISPFSCLKDRHDFGLPQEEFDGNQFQKTQAISVLHEMIQQTFNLFSTEDSSAAWEQSLLEKFSTELYQQLNNLEACVIQEVGMEETPLMNEDSILAVRKYFQRITLYLTEKKYSPCAWEVVRAEIMRSLSFSTNLQKILRRKD
-
Molecular Weight
25.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
IFNA17, also known as interferon alpha-17, is a member of the type I interferon family, which plays a critical role in the immune response against viral infections and tumor growth. Research into IFNA17 has gained momentum due to its unique biological properties compared to other interferons, making it a potential candidate for therapeutic applications in antiviral treatments and cancer immunotherapy. Unlike its counterparts, IFNA17 displays distinct receptor interactions and signaling pathways, which may result in different cellular outcomes, thus prompting investigations into its efficacy and safety as a therapeutic agent. Studies have suggested that IFNA17 may enhance antiviral responses and exhibit anti-proliferative effects on certain cancer cells, opening avenues for novel treatment strategies. Moreover, the potential for recombinant production of IFNA17 facilitates a deeper understanding of its structure-function relationship and allows for the exploration of engineered variants that could improve its therapeutic potency. As researchers continue to unravel the complexities of IFNA17, its implications in precision medicine and combination therapies are becoming increasingly significant, positioning it as a promising focus for further exploration in the quest for innovative treatments against infectious diseases and malignancies.
